Smashed Peaches

Drug Research Studies

FibroGen, Inc. (FGEN) At $37.31 Forms Bottom; Lombard Odier Asset Management Switzerland Sa Cut By $22.50 Million Its Pfizer (PFE) Position – MЕSА Wееkly

Lombard Odier Asset Management Switzerland Sa decreased Pfizer Inc (PFE) stake by 96.72% reported in 2019Q2 SEC filing. Lombard Odier Asset Management Switzerland Sa sold 523,339 shares as Pfizer Inc (PFE)’s stock declined 4.73%. The Lombard Odier Asset Management Switzerland Sa holds 17,724 shares with $768,000 value, down from 541,063 last quarter. Pfizer Inc now has $201.00B valuation. The stock increased 1.54% or $0.55 during the last trading session, reaching $36.34. About 2.54 million shares traded. Pfizer Inc. (NYSE:PFE) has risen 0.65% since October 11, 2018 and is uptrending. It has outperformed by 0.65% the S&P500. Some Historical PFE News: 01/05/2018 – Pfizer New Drug Sales Show Strength as Investors Wait for M&A; 06/03/2018 – GLYCOMIMETICS: RIVIPANSEL PHASE 3 TRIAL END ON TRACK FOR 2H’18; 25/05/2018 – STAT Plus: Pharmalittle: Mylan pressures Pfizer to fix EpiPen production problems; AstraZeneca cancer drug hits goal; 17/04/2018 – HEALTH CANADA SAYS EFFORTS INCLUDE EXPLORING ACCESS TO INTERNATIONAL EPIPEN SUPPLY PFE.N MYL.O; 03/04/2018 – PFIZER INC PFE.N SAYS ALLOGENE WILL RECEIVE RIGHTS TO ONE CLINICAL ASSET FROM SERVIER CALLED UCART19; 29/03/2018 – Pfizer Announces Positive Topline Results From Phase 3 ATTR-ACT Study Of Tafamidis In Patients With Transthyretin; 17/04/2018 – JNJ: NO GENERIC COMPETITION EXEPCTED FOR ZYTIGA IN 2018; 01/05/2018 – Health Care Down After Merck, Pfizer Earnings — Health Care Roundup; 17/05/2018 – LYRICA® (PREGABALIN) ORAL SOLUTION CV PHASE 3 TRIAL IN; 19/04/2018 – ASEMBIA CLIENTS GAIN ACCESS TO PFIZER ONCOLOGY PRODUCTS

FibroGen, Inc. (FGEN) formed multiple bottom with $36.19 target or 3.00% below today’s $37.31 share price. FibroGen, Inc. (FGEN) has $3.24B valuation. The stock increased 1.80% or $0.66 during the last trading session, reaching $37.31. About 44,768 shares traded. FibroGen, Inc. (NASDAQ:FGEN) has declined 23.40% since October 11, 2018 and is downtrending. It has underperformed by 23.40% the S&P500. Some Historical FGEN News: 09/05/2018 – FibroGen 1Q Rev $31.9M; 28/03/2018 – Andes Technology Corp. to Present & Exhibit at Design & Reuse IP SOC Conference; 31/05/2018 – ASTELLAS PHARMA INC – ROXADUSTAT WAS WELL TOLERATED IN STUDY; 21/05/2018 – FibroGen Presents Latest Data From PRAISE Phase 2b Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis at American Thoracic Society 2018; 06/04/2018 – HK Bourse: Announcement From Pacific Andes International Holdings Ltd; 13/03/2018 Announcing The First Andes Summit – Indigenous Wisdom-Keepers to Gather With People of The North to lnitiate a New Commitment to Earth Healing; 23/04/2018 – DJ FibroGen Inc, Inst Holders, 1Q 2018 (FGEN); 09/05/2018 – FIBROGEN 1Q LOSS/SHR 50C, EST. LOSS/SHR 51C; 25/04/2018 – $GSK catching up quickly in HIF vs. $FGEN and $AKBA Positive results in house from first of three Ph3 for daprodustat in Japan; 18/04/2018 – The Andes Summit: More Than Ayahuasca – A Re-Validation of the Cultural Heritage of Ecuador’s Ancient Indigenous Wisdom

Among 2 analysts covering FibroGen (NASDAQ:FGEN), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. FibroGen has $65 highest and $6500 lowest target. $65’s average target is 74.22% above currents $37.31 stock price. FibroGen had 5 analyst reports since April 12, 2019 according to SRatingsIntel. As per Monday, August 26, the company rating was maintained by Mizuho.

Analysts await FibroGen, Inc. (NASDAQ:FGEN) to report earnings on November, 14. They expect $-0.59 earnings per share, down 18.00% or $0.09 from last year’s $-0.5 per share. After $1.26 actual earnings per share reported by FibroGen, Inc. for the previous quarter, Wall Street now forecasts -146.83% negative EPS growth.

Lombard Odier Asset Management Switzerland Sa increased Sl Green Rlty Corp (NYSE:SLG) stake by 3,771 shares to 6,333 valued at $509,000 in 2019Q2. It also upped Starbucks Corp (NASDAQ:SBUX) stake by 24,690 shares and now owns 38,181 shares. Bristol Myers Squibb Co (NYSE:BMY) was raised too.

More notable recent Pfizer Inc. (NYSE:PFE) news were published by: which released: “Is Pfizer (NYSE:PFE) A Risky Investment? – Yahoo Finance” on October 08, 2019, also with their article: “Pfizer (NYSE: PFE) buys Durham facility with plans to renovate as Triangle expansion continues – Triangle Business Journal” published on September 26, 2019, published: “Where Will Pfizer Be in 5 Years? – The Motley Fool” on September 28, 2019. More interesting news about Pfizer Inc. (NYSE:PFE) were released by: and their article: “Were Hedge Funds Right About Souring on Pfizer? – Yahoo Finance” published on October 08, 2019 as well as‘s news article titled: “Leaner Pfizer Positioned to Boost R&D Output – Yahoo Finance” with publication date: September 11, 2019.

Analysts await Pfizer Inc. (NYSE:PFE) to report earnings on October, 29. They expect $0.62 EPS, down 20.51% or $0.16 from last year’s $0.78 per share. PFE’s profit will be $3.43B for 14.65 P/E if the $0.62 EPS becomes a reality. After $0.80 actual EPS reported by Pfizer Inc. for the previous quarter, Wall Street now forecasts -22.50% negative EPS growth.

Among 2 analysts covering Pfizer (NYSE:PFE), 0 have Buy rating, 0 Sell and 2 Hold. Therefore 0 are positive. Pfizer has $3800 highest and $3600 lowest target. $37’s average target is 1.82% above currents $36.34 stock price. Pfizer had 8 analyst reports since April 16, 2019 according to SRatingsIntel. Morgan Stanley maintained the shares of PFE in report on Tuesday, August 27 with “Equal-Weight” rating. The rating was upgraded by DZ Bank on Wednesday, August 28 to “Hold”.

Investors sentiment increased to 0.84 in 2019 Q2. Its up 0.08, from 0.76 in 2019Q1. It is positive, as 51 investors sold PFE shares while 714 reduced holdings. 122 funds opened positions while 520 raised stakes. 3.85 billion shares or 0.77% less from 3.88 billion shares in 2019Q1 were reported. Main Street Ltd Liability holds 0.11% or 11,176 shares. Commerzbank Aktiengesellschaft Fi stated it has 1.06 million shares or 0.32% of all its holdings. Moreover, South Texas Money Mgmt Limited has 0.09% invested in Pfizer Inc. (NYSE:PFE). Epoch Invest Prns has 1.75% invested in Pfizer Inc. (NYSE:PFE) for 8.94 million shares. Polaris Greystone Financial Grp Limited Liability Company invested in 9,729 shares. Nomura Asset Mngmt Limited reported 0.55% stake. Clifford Swan Inv Counsel Limited Company holds 1.03% in Pfizer Inc. (NYSE:PFE) or 453,351 shares. Truepoint holds 9,197 shares. Janney Montgomery Scott Limited Liability Corporation reported 0.67% stake. Wunderlich Managemnt holds 1.27% or 44,016 shares. Thornburg Invest Mgmt Incorporated stated it has 2.62M shares or 1.09% of all its holdings. Grassi Investment stated it has 222,234 shares. Monetary owns 24,156 shares for 0.4% of their portfolio. Somerville Kurt F holds 0.24% or 28,172 shares in its portfolio. Sheets Smith Wealth Mgmt accumulated 47,721 shares.

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.